Table 1 Rubraxanthone efficacy, as determined using cell-based assays. Results are presented as mean ± standard error of the mean (SEM) for three biologically independent experiments.

From: Promising SARS-CoV-2 main protease inhibitor ligand-binding modes evaluated using LB-PaCS-MD/FMO

 

EC50 (µM)

CC50 (µM)

Vero E6

Vero E6

Calu-3

Rubraxanthone

4.00 ± 1.75

26.61 ± 2.95

> 50